This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Skip to main content
null
Scholarly Review Journal
  • Menu
  • Articles
    • Advocacy
    • Architecture
    • Art
    • Artificial Intelligence
    • Astronomy
    • Biology
    • Business
    • Chemistry
    • Computer Science
    • Crime
    • Economics
    • Education
    • Engineering
    • Environment
    • Ethics
    • Fashion
    • History
    • Law
    • Literature
    • Machine Learning
    • Mathematics
    • Media
    • Medicine
    • Mental Health
    • Music
    • Mythology
    • Philosophy
    • Political Science
    • Politics
    • Psychology
    • Religion
    • Sociology
    • Sport
    • Technology
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Publication Calendar
  • Contact
  • AI Policy
  • IRB Policy
  • Model Paper
  • Methodology & Citations
  • search
  • RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:58827/feed
ISSN 2996-8380
Medicine
September 15, 2026 CEST

Applications of Olaparib and Durvalumab Combination Therapy for a Founder BRCA1 Mutation in the Chinese Han Population: A Literature Review

Claire Li,
cancergermline BRCA1/2 mutationsBRCA1PARP inhibitorsimmunotherapydurvalumabolaparibovarian cancerbreast cancerChinese Han
Copyright Logoccby-4.0 • https://doi.org/10.70121/001c.169631
Photo by Sangharsh Lohakare on Unsplash
Scholarly Review Journal
Li, Claire. 2026. “Applications of Olaparib and Durvalumab Combination Therapy for a Founder BRCA1 Mutation in the Chinese Han Population: A Literature Review.” Scholarly Review Journal Fall 2026 (17). https://doi.org/10.70121/001c.169631.
Save article as...▾

View more stats

Powered by Scholastica, the modern academic journal management system